Seattle clinical-stage biotechnology company Kineta Inc. on Monday said it signed a licensing agreement potentially worth more than $500 million to develop new cancer immunotherapies with drug giant Pfizer.
Kineta said its Kineta Immuno-Oncology unit will receive $15 million upfront from Pfizer and will be eligible for up to $505 million in potential milestone payments.
Kineta said the companies will work to develop and test small molecule agonists that target RIG-I, an innate immunostimulatory pathway that can elicit immunogenic cell death in tumors, providing direct tumor cell killing and enhanced antitumor immune responses.
New York-based Pfizer will receive exclusive rights to Kineta’s RIG-I screening platform and related compounds and technologies.
Kineta in April said it agreed to collaborate with Roche Holding Genentech on development of a nonopioid pain therapy in a deal that included up to $359 million on potential milestone payments.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.